alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Mr. David K. Paylor, Director 

Virginia Department of Environmental Quality 

629 East Main Street 

Richmond, Virginia 232 1 9 

Dear Mr. Paylor: 

On March 12,2008, the U.S. Environmental Protection Agency (EPA) revised the 

national ambient air quality standards (NAAQS) for ozone to provide increased protection of 

public health and welfare from ozone pollution. The new primary ozone standard was lowered 

from 0.08 parts per million (ppm) to 0.075 ppm based on numerous epidemiological studies 

conducted during-the past decade in which many of the health effects associated with ozone 

exposure have been demonstrated at and below the level of the 0.08 ppm standard, which was 

promulgated in 1997. These include a range of serious respiratory effects and increased 

premature mortality. EPA also strengthened the secondary 8-hour ozone standard, making it 

identical to the revised primary standard, to protect against welfare effects such as impacts on 

vegetation and forested ecosystems. 

Within one year of promulgation of a new or revised NAAQS, section 107(d)(l)(A) of 

the Clean Air Act requires the Governor of each state to submit to EPA a list of all areas in the 

state, recommending designations for each as "attainment," "nonattainment," or "unclassifiable" 

with respect to the new or revised standard. Therefore, EPA asks that you provide your 

designation recommendations, including appropriate area boundaries, to EPA by March 12,2009 

with respect to the revised ozone NAAQS. Establishing area designations is a key step in the 

process of providing the health protections that the Clean Air Act mandates. Areas that are 

designated as not attaining the air quality standards will be required to adopt plans to reduce ambient concentrations of ozone. 

The enclosed memorandum provides guidance to state and local air pollution control 

agencies and Tribes on the process for designating areas under the'2008 revised ozone standard. 

EPA plans to announce our intended designations as early as possible after receipt of your 

recommendations, but no later than 120 days prior to promulgating final designations. 

Following the announcement of intended designations, states and Tribes will have the 

opportunity to comment on any modifications EPA proposes to their recommendations. In 

accordance with section 107(d)(l)(B) of the Clean Air Act, we intend to issue final designations 

by March 12,201 0 (although that deadline may be extended up to one additional year if EPA 

determines that insufficient information is available to establish designations by that date). Our 

designations will be based on the most recent three years of certified, quality assured monitoring 

data available. Ozone nonattainment areas will be classified at the time of designation. The 

approach EPA will use to classify nonattainment areas under the 2008 revised ozone NAAQS 

will be established through a separate notice-and-comment rulemaking. 
Donald S. Welsh 

Regional ~dministrator 

Enclosure 

cc: Mr. Michael G. Dowd, Air Quality Division Director 

Virginia Department of Environmental Quality
Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER  PURSUANT TO 18 U.S.C. SECTION 1350,  AS ADOPTED PURSUANT TO SECTION 906  OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K for the fiscal year ended December 31, 2009 of
OpenTable, Inc. (the "Company") as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Jeffrey Jordan, Chief Executive Officer of the Company, certify,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

/s/ JEFFREY JORDAN Jeffrey Jordan Chief Executive Officer
(Principal Executive Officer)Date: March 11, 2010


This
certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any
filing of OpenTable, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the
Form 10-K), irrespective of any general incorporation language contained in such filing.

---



QuickLinks
### Index for References Cited in Reid Gardner Generating Station Final Rule (FIP Revision)

EPA

‐ R09

‐ OAR

‐ 2013

‐ 0148

OTHER documents

Document Name in www.regulations.gov

Docket Index for Final Action

Fact Sheet

### Index for References Cited in Reid Gardner Generating Station Final Rule (FIP Revision )

EPA

‐ R09

‐ OAR

‐ 2013

‐ 0148

Federal Register Notice

Footnote

Number Document Name as referenced in FRN Document Name in Docket on www.regulations.gov or

document ID number if already posted prior to final rule

1 Transcript from April 29, 2013 public hearing EPA

‐ R09

‐ OAR

‐ 2013

‐ 0148, document number 0014

2 Comment letter from Dan Galpern on behalf of Sierra Club, NPCA,

and Moapa Band of Paiute Indians, dated May 28, 2013 EPA

‐ R09

‐ OAR

‐ 2013

‐ 0148, document number 0013

3 Comment letter from Starla Lacy, NV Energy, dated May 14, 2013;

and Comment letter from Rob Bamford, Nevada Division of

Environmental Protection, dated May 15, 2013 EPA

‐ R09

‐ OAR

‐ 2013

‐ 0148, document number 0010 and

0009

4 Letter from Starla Lacy to Anita Lee, dated January 31, 2013 EPA

‐ R09

‐ OAR

‐ 2013

‐ 0148, document number 0004

5 http://www.leg.state.nv.us/Session/77th2013/Reports/history.cfm

?billname=SB123 Not posted to docket. See web link.

6 77 FR 50936 (August 23, 2012) Federal Register notices available through

http://www.gpo.gov/fdsys/

7 Explanatory text, not a reference.

8 75 FR 45485 (August 3, 2012); 75 FR 59090 (September 27, 2010);

78 FR 1149 (January 8, 2013) Federal Register notices available through

http://www.gpo.gov/fdsys/

9 77 FR 20218 (April 3, 2012) Federal Register notices available through

http://www.gpo.gov/fdsys/
<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-END>                               SEP-30-1999
<CASH>                                     549,659,000
<SECURITIES>                                         0
<RECEIVABLES>                              133,852,000
<ALLOWANCES>                                 1,032,000
<INVENTORY>                                          0
<CURRENT-ASSETS>                           772,368,000
<PP&E>                                     680,175,000
<DEPRECIATION>                              41,364,000
<TOTAL-ASSETS>                           3,017,877,000
<CURRENT-LIABILITIES>                      358,246,000
<BONDS>                                  1,391,113,000
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       632,000
<OTHER-SE>                               1,134,128,000
<TOTAL-LIABILITY-AND-EQUITY>             3,017,877,000
<SALES>                                              0
<TOTAL-REVENUES>                           527,185,000
<CGS>                                      371,811,000
<TOTAL-COSTS>                              465,822,000
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                        (25,741,000)
<INCOME-PRETAX>                             37,273,000
<INCOME-TAX>                              (22,028,000)
<INCOME-CONTINUING>                         15,245,000
<DISCONTINUED>                                       0
<EXTRAORDINARY>                            (2,620,000)
<CHANGES>                                            0
<NET-INCOME>                                12,625,000
<EPS-BASIC>                                     0.19
<EPS-DILUTED>                                     0.18




</TABLE>
EX-10.6





 Exhibit 10.6 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item
601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 

October 15, 2015 
 Dr. Zheng Wei 

Connect Biopharm LLC 
 4128 Via Candidiz, Suite 145 

San Diego CA 92130 
  

			
	Re:	  	 Notice of Intention to Cease Prosecution of All National Phase

Applications Corresponding to International Application [***]


 Dear Dr. Wei: 

Connect BioPharm LLC (referred to herein as “Company”) and Arena Pharmaceuticals, Inc. (“Licensor”) entered into an
Exclusive License Agreement with an effective date of June 19, 2012 (the “Agreement”), which you signed on behalf of Company. For your convenience please find a copy of the Agreement attached. 

This notice is provided pursuant to Section 5.3 (“Patent Prosecution and Maintenance”) of the Agreement. Section 5.3(a)
specifies that Licensor may at any time cease to provide the Patent Prosecution Services (which are defined in the same Section to refer to the filing, prosecution and maintenance of License Patents and Program Patents), by written notice to
Company. Licensor hereby provides written notice to Company that Licensor does not intend to continue providing these Patent Prosecution Services. If Company elects to assume responsibility for prosecuting and maintaining any of such applications
Company shall have the right to do so at its own cost. 
 For the avoidance of doubt, this letter refers only to the transfer of
responsibility for the prosecution of the above-identified applications. Ownership of the applications remains with Licensor. The obligations of Company under the Agreement, including the consultation provision of 5.3(b) and the notice
provisions of Section 5.3(d), remain in effect. 
 If you have any questions, please contact [***]. 

 

	
	Sincerely,
	
	/s/ Steven W. Spector            
	Steven W. Spector
	Executive Vice President and General Counsel
<PAGE>

                                                                    EXHIBIT 32.1

                CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

      I, Scott D. Dorfman, Chief Executive Officer of Innotrac Corporation (the
"Company"), certify, pursuant to 18 U.S.C. Section 1350 as adopted by Section
906 of the Sarbanes-Oxley Act of 2002, that:

(1)   the Quarterly Report on Form 10-Q of the Company for the quarter ended
      March 31, 2005 (the "Report") fully complies with the requirements of
      Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)   the information contained in the Report fairly presents, in all material
      respects, the financial condition and results of operations of the
      Company.

Dated: May 16, 2005

                                            /s/ Scott D. Dorfman
                                            --------------------
                                            Scott D. Dorfman
                                            President, Chief Executive Officer
                                            and Chairman of the Board
Exhibit 32.2

                            CERTIFICATION PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
                            (18 U.S.C. SECTION 1350)

In connection with this annual filing of DNAPrint genomics, Inc., a Utah
corporation (the "Company"), on Form 10-KSB/A for the year ended December 31,
2004 as filed with the Securities and Exchange Commission (the "Report"), I,
Monica Tamborini, Chief Financial Officer of the Company, certify, pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350), that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material
respects, the financial condition and resulingery. I think this should be
deleted, but I updated it in case you want to keep in



                                          By: /s/ Monica Tamborini
                                              ------------------------
                                              Monica Tamborini
                                              Chief Financial Officer
                                              Date: March 31, 2005
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-30-2000
<PERIOD-START>                             JAN-02-2000
<PERIOD-END>                               APR-01-2000
<CASH>                                             764
<SECURITIES>                                         0
<RECEIVABLES>                                      525
<ALLOWANCES>                                         0
<INVENTORY>                                     39,012
<CURRENT-ASSETS>                                41,161
<PP&E>                                           9,185
<DEPRECIATION>                                   3,743
<TOTAL-ASSETS>                                  47,576
<CURRENT-LIABILITIES>                           26,557
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             7
<OTHER-SE>                                      19,266
<TOTAL-LIABILITY-AND-EQUITY>                    47,576
<SALES>                                         19,322
<TOTAL-REVENUES>                                19,322
<CGS>                                           13,235
<TOTAL-COSTS>                                   13,235
<OTHER-EXPENSES>                                 5,521
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 187
<INCOME-PRETAX>                                    377
<INCOME-TAX>                                       148
<INCOME-CONTINUING>                                229
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       229
<EPS-BASIC>                                        .03
<EPS-DILUTED>                                      .03


</TABLE>
THE UNITED STATES DISTRICT COURT

 FOR THE EASTERN DISTRICT OF PENNSYLVANIA

 

IN RE: IMMODIUM ADVANCED

ANTITRUST LITIGATION

CIVIL ACTION Nos. 

02-4105

02-4149

02-4180

02-4197

02-4362

02-4386

02-4387

02-4476

02-4530

02-6797

02-6993

O R D E R

AND NOW, this 1st day of December, 2003, pursuant to this court’s Order dated

September 10, 2003 in In re: Immodium Advanced Antitrust Litigation (Civ. A. No. 02-4093,

Doc. No. 24), it is hereby ORDERED that the cases listed above are dismissed.

BY THE COURT:

 

MARVIN KATZ, S.J.

Case 2:02-cv-04105-MK Document 11 Filed 12/01/2003 Page 1 of 1
# C_2017063EN.01001201.xml

| 27.2.2017 | EN | Official Journal of the European Union | C 63/12 |
| --- | --- | --- | --- |

27.2.2017

EN

Official Journal of the European Union

C 63/12

---

Order of the Court of Justice (Eighth Chamber) of 10 November 2016 (request for a preliminary ruling from the Dublin District Court — Ireland) — Criminal proceedings against Owen Pardue

(Case C-321/16) (1)

1

((Reference for a preliminary ruling - Charter of Fundamental Rights of the European Union - Preamble and Articles 6, 20, 41, 47 and 48 - Powers of the national criminal prosecution authorities - Failure to implement EU law - Article 53(2) of the Rules of Procedure of the Court - Clear lack of jurisdiction of the Court))

(2017/C 063/17)

Language of the case: English

Referring court

Referring court

Dublin District Court

Criminal proceedings against

Criminal proceedings against

Owen Pardue

Operative part of the order

Operative part of the order

The Court of Justice of the European Union clearly lacks jurisdiction to answer the questions referred by the Dublin District Court (Ireland) by decision of 27 May 2016.

---

(1)  OJ C 279, 1.6.2016

1

---
IN THE UNITED STATES DISTRICT COURT

FOR THE EASTERN DISTRICT OF PENNSYLVANIA

ANGELA and CHARLES RUSS, :

: CIVIL ACTION NO. 02-CV-4255

Plaintiffs, :

:

v. :

:

BAYER CORPORATION;

BAYER AG;

GLAXOSMITHKLINE, PLC;

GLAXOSMITHKLINE;

SMITHKLINE BEECHAM

:

:

:

:

:

ENTRY OF APPEARANCE

:

Defendants. :

ENTRY OF APPEARANCE

To the Clerk of the Court:

Kindly enter the appearances of Hope S. Freiwald, Aline Fairweather, Erin

Brennan and Kirstin J. Miller as attorneys for defendant SmithKline Beecham Corporation d/b/a

GlaxoSmithKline.

Respectfully Submitted,

_____________________________ _____________________________

Hope S. Freiwald Aline Fairweather

_____________________________ _____________________________

Erin Brennan Kirstin J. Miller

DECHERT PRICE & RHOADS

4000 Bell Atlantic Tower

1717 Arch Street

Philadelphia, PA 19103-2793

(215) 994-4000

Case 2:02-cv-04255-JD Document 7 Filed 10/04/2002 Page 1 of 1
No. 60709.

#### Paillard Products, Inc. *v.*United States,

protest 280311-K (New York).

Opinion by

Rao, J.

In accordance with stipulation of counsel that the items in question are entireties with typewriters, being portable typewriters, and that the cases are the usual containers for such typewriters, the claim of the plaintiff was sustained.
[Federal Register Volume 88, Number 217 (Monday, November 13, 2023)]
[Notices]
[Page 77596]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-24926]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Heart, Lung, and Blood Institute; Notice of Closed 
Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Heart, Lung, and Blood Institute 
Special Emphasis Panel; Mentored Patient Oriented Review.
    Date: November 17, 2023.
    Time: 1:00 p.m. to 2:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Rockledge I, 6705 
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Fungai Chanetsa, Ph.D., MPH, Scientific Review 
Officer, Office of Scientific Review/DERA, National Heart, Lung, and 
Blood Institute National Institutes of Health, 6705 Rockledge Drive, 
Room 206-B, Bethesda, MD 20817, (301) 402-9394, 
<a href="/cdn-cgi/l/email-protection#1f796a71787e76317c777e717a6b6c7e5f71767731787069"><span class="__cf_email__" data-cfemail="d3b5a6bdb4b2bafdb0bbb2bdb6a7a0b293bdbabbfdb4bca5">[email protected]</span></a>.

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, 
National Center for Sleep Disorders Research; 93.837, Heart and 
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, 
Blood Diseases and Resources Research, National Institutes of 
Health, HHS)

    Dated: November 7, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-24926 Filed 11-9-23; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
No. 55141.

#### Sun Import Co., Inc. *v.*United States,

protests 29167-K, etc. (New York).

Opinion by

Lawrence, J.

The protests were dismissed.
No. 56327.

protests 168337-K, etc. (New York).

#### Albert Bonnier Publishing House, Inc., et al. *v.*United States,

Opinion by

Rao, J.

The protests were dismissed.
COURT OF APPEALS

EIGHTH DISTRICT OF TEXAS

EL PASO, TEXAS

DALTON JAMES BENNETT , JR. A/K/A

DALTON JAMES BENNETT

,

Appellant,

v.

THE STATE OF TEXAS

,

Appellee. §

§

§

§

§ No. 08

- 13

- 00138

- CR

Appeal from the

372 nd District Court

of Tarrant County, Texas

(TC# 1244131D)

J U D G M E N T

The Court has considered this cause on the record and concludes the judgment of

conviction should be modified to reflect that the trial court assessed the punishment in

Appellant’s case. We therefore affirm the judgment of the trial court as modified. This decision

shall be certified below for observance.

IT IS SO ORDERED THIS 30TH DAY OF JUNE, 2015.

STEVEN L. HUGHES, Justice

Before McClure, C.J., Rodriguez, and Hughes, JJ.
EXHIBIT 32.1



CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with
the Quarterly Report of Bayou City Exploration, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2012
as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Charles T. Bukowski, Chief
Executive Officer and President of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906
of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:



| | 1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange
Act of 1934; and
| | -- | ---------------------------------------------------------------------------------------------------------------------



| | 2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company
| | -- | ---------------------------------------------------------------------------------------------------------------------------------------------------



/s/ Charles T. Bukowski

Charles T. Bukowski

Chief Executive Officer and President



August 14, 2012



This certification accompanies the Report
pursuant to § 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act
of 2002, be deemed filed by the Company for purposes of § 18 of the Securities Exchange Act of 1934, as amended.



A signed original of this certification
has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or
its staff upon request.